Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

878
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
878
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

406
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
406
Cancer Vaccines01:30

Cancer Vaccines

882
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
882
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated amyloid neurodegeneration in HIV-1-infected APP-KI Alzheimer's disease mice.

bioRxiv : the preprint server for biology·2026
Same author

CAR Treg therapies for neurodegenerative diseases.

iScience·2026
Same author

A Hypothesis-Generating Pharmacologic Profile for Sargramostim Treatment of Parkinson's Disease.

Cellular and molecular neurobiology·2026
Same author

Colostrum extracellular vesicles are neuroprotective in models of Parkinson's disease.

Theranostics·2026
Same author

An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail.

Nature communications·2026
Same author

Extracellular vesicle-based therapies for neurodegenerative diseases.

NeuroImmune pharmacology and therapeutics·2026

Related Experiment Video

Updated: Dec 30, 2025

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.9K

Immunotherapy for Parkinson's disease.

Aaron D Schwab1, Mackenzie J Thurston1, Jatin Machhi1

  • 1Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5110, United States of America.

Neurobiology of Disease
|January 25, 2020
PubMed
Summary
This summary is machine-generated.

New Parkinson's disease (PD) therapies focus on the brain's immune microenvironment. Restoring immune balance, particularly with regulatory T cells, shows promise for neuroprotection in PD and other neurodegenerative diseases.

Keywords:
Alzheimer’s diseaseEffector T cellsGranulocyte-macrophage colony stimulating factorImmune homeostasisImmune transformationIschemic strokeNeurodegenerationNeurodegenerative disordersNeuroinflammationNeuroprotectionNigrostriatal degenerationParkinson’s diseaseRegulatory T cellsTeffsTraumatic brain injuryTregs

More Related Videos

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.1K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.3K

Related Experiment Videos

Last Updated: Dec 30, 2025

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.9K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.1K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.3K

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Parkinson's disease (PD) prevalence is rising, necessitating effective treatments.
  • Current therapies like stem cell replacement and alpha-synuclein clearance lack long-term clinical benefit.
  • Neuroinflammation, involving disordered immune functions, is a key factor in neurodegenerative disease pathogenesis.

Purpose of the Study:

  • To explore a novel therapeutic strategy targeting the brain's immune microenvironment for neurodegenerative diseases.
  • To investigate the potential of restoring immune homeostasis for neuroprotection.
  • To focus on enhancing regulatory T cells (Tregs) to counteract detrimental effector cells.

Main Methods:

  • Investigating the role of innate and adaptive immune functions in neurodegeneration.
  • Developing interventions to restore the brain's homeostatic immune environment.
  • Focusing on increasing the number and function of regulatory T cells (Tregs).

Main Results:

  • Early laboratory and clinical investigations demonstrate neuroprotective outcomes from immune-modulating interventions.
  • Evidence suggests that enhancing Tregs can shift the immune balance away from inflammation.
  • This approach shows potential to mitigate neuroinflammation and neurodegeneration.

Conclusions:

  • Modulating the brain's immune microenvironment represents a promising therapeutic avenue for Parkinson's disease.
  • Restoring immune homeostasis, specifically by boosting Tregs, offers neuroprotective benefits.
  • This immunotherapeutic strategy may extend to other neurodegenerative conditions like Alzheimer's disease, stroke, and traumatic brain injury.